To comparative pain intensity, chest mobility, cough strength, muscle strength, physicalactivity levels and quality of life in Parkinson's patients with post-COVID-19 andwithout post-COVID-19 was aimed in current study. Knowledge in the literature regardingthis topic is still obscure.
Acute worsening and long-term sequelae of motor and non-motor symptoms have also been
described in Parkinson's patients during and after SARS-CoV-2 infection, which is also
known as prolonged COVID. The effects of COVID-19 on pain, chest mobility, cough
strength, muscle strength, physical activity levels and quality of life in Parkinson's
patients are still unclear today. For this reason, in this study, it was aimed to
comparatively investigate pain, chest mobility, cough strength, muscle strength, physical
activity levels and quality of life in Parkinson's patients with COVID-19 and without
COVID-19 and to show the relationships between these outcome measures.
Other: Physical Evaluations of post-COVID-19 individuals
In this research, the data of Parkinson's patients who have had COVID-19 will be
collected face to face. Chest mobility, cough strength, muscle strength, physical
activity and quality of life will be evaluated in all Parkinson's patients. The data to
be obtained through all these evaluations will be collected from at one time and in a
time lasting maximum of about 1 hour. Step count tracking with pedometer will be done for
3 days for each individual.
Other: Physical Evaluations of non-post-COVID-19 individuals
In this research, the data of Parkinson's patients who have not had COVID-19 will be
collected face to face. Chest mobility, cough strength, muscle strength, physical
activity and quality of life will be evaluated in all Parkinson's patients. The data to
be obtained through all these evaluations will be collected from at one time and in a
time lasting maximum of about 1 hour. Step count tracking with pedometer will be done for
3 days for each individual.
Inclusion Criteria for Parkinson's patients with post-COVID-19;
- Being diagnosed with COVID-19 at least 12 weeks ago and recovered,
- Being over 18 years old,
- Volunteering to participate in the research,
- Being diagnosed with Parkinson's disease
- Comorbid conditions (such as hypertension, diabetes) are under control
- Being able to perceive assessments (Standardized Mini Mental Test score of 24 and
above)
- Having the ability to ambulate and walk independently
- Being in stage 1 - 4 according to the Modified Hoehn-Yahr Scale
Inclusion criteria for Parkinson's patients without post-COVID-19;
- Not being diagnosed or suspected of COVID-19
- Being over 18 years old,
- Volunteering to participate in the research,
- Being diagnosed with Parkinson's disease
- Having comorbid conditions (such as hypertension, diabetes) which are under control
- Being able to perceive assessments (Standardized Mini Mental Test score of 24 and
above)
- Having the ability to ambulate and walk independently
- Being in stage 1 - 4 according to the Modified Hoehn-Yahr Scale
Exclusion criteria for Parkinson's patients with and without post-COVID-19;
- Sudden drug or dose change during the study period
- A history of any acute/chronic orthopedic, cardiovascular, pulmonary, psychiatric or
neuromuscular disease that may prevent measurements from being made.
- Having had myocardial infarction and pulmonary embolism in the last 30 days,
- Having a history of additional neurological (stroke, head trauma, peripheral nerve
diseases, brain and spinal cord tumors, etc.) diseases other than Parkinson's
disease
- Having severe vision loss or vestibular dysfunction
- Patients with blood pressure values above 140/90 and below 90/50 in blood pressure
measurements made before the study, with arrhythmia on ECG, with a history of
shortness of breath and/or palpitation
Izmir Democracy University
İzmir, Turkey
Investigator: GÜLŞAH BARĞI, PHD
Contact: +905317938766
gulsah.bargi@idu.edu.tr
GÜLŞAH BARĞI
+90 232 299 0739
gulsahbargi35@gmail.com
MERVE ŞAHİN